Bicara Therapeutics Inc. ... (BCAX)
NASDAQ: BCAX
· Real-Time Price · USD
14.79
0.42 (2.92%)
At close: May 01, 2025, 3:59 PM
14.51
-1.89%
Pre-market: May 02, 2025, 06:11 AM EDT
2.92% (1D)
| Bid | 13.33 |
| Market Cap | 806.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -68M |
| EPS (ttm) | -4.05 |
| PE Ratio (ttm) | -3.65 |
| Forward PE | -4.93 |
| Analyst | Buy |
| Ask | 17.13 |
| Volume | 715,792 |
| Avg. Volume (20D) | 572,395.7 |
| Open | 14.66 |
| Previous Close | 14.37 |
| Day's Range | 13.95 - 14.80 |
| 52-Week Range | 8.91 - 28.09 |
| Beta | -1.49 |
About BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 55
Stock Exchange NASDAQ
Ticker Symbol BCAX
Website https://www.bicara.com
Analyst Forecast
According to 7 analyst ratings, the average rating for BCAX stock is "Buy." The 12-month stock price forecast is $33, which is an increase of 123.12% from the latest price.
Stock Forecasts4 months ago
+7.98%
Bicara Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
